Overnight Market report, page-742

Like your sense of irony (sarcasm) Camban!
Definitely needed at moment

IMM remains a cellar dweller despite trials going good/great and data confirmation of efti working well in combo scenarios in hard to treat and unmet need cancers - ie mBC and NSCLC/HNC.

Long term investor (all capital raises last 12 years).
Ultimately as an investor (as opposed to pure philanthropist) I expect a return on funds better than blue chips.

The longer our single platform efti remains in multiple P1/2 trials and not FDA approved and therefore not monetised the nearer new and novel drugs being fast tracked could (will) overtake us.

Not a negative. Simply evolution.

Read a recent report saying that the longer BP keeps potential competing drugs in the clinical in combo with their drugs the better for them to develop own/similar drugs in-house and not have to buy-out or in-license the likes of Immutep. P3 trials could be the death knoll.

After well over a decade, I want to see a deal done with BP very soon. Merck maybe. BMS maybe. A few dark horses are in the maybe stable too.

While we are still in a cash position of relative strength, now is the time Marc.

All imo of course.